Mark T Reding MD
Assistant Professor, Medicine, University of Minnesota Medical School
Join to View Full Profile
420 Delaware St SeMmc 480Minneapolis, MN 55455
Phone+1 612-625-1104
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mark Reding, MD is an oncologist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with M Health Fairview University of Minnesota Medical Center and is an Assistant Professor at University of Minnesota Medical School.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1996 - 1999- University of MinnesotaResidency, Internal Medicine, 1992 - 1995
- University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
MN State Medical License 1994 - 2026
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014-2017
- CMS Meaningful Use Stage Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014-2017
Publications & Presentations
PubMed
- 4 citationsCorrection: Damoctocog Alfa Pegol, a PEGylated B-domain Deleted Recombinant Extended Half-life Factor VIII for the Treatment of Hemophilia A: A Product Review.Mark T Reding, Shadan Lalezari, Gili Kenet, Giovanni Di Minno, Jonathan Ducore
Drugs in R&D. 2025-03-01 - 1 citationsRecombinant factor VIIa: new insights into the mechanism of action through product innovation.Miguel A Escobar, Maureane Hoffman, Giancarlo Castaman, Cedric Hermans, Johnny Mahlangu
Research and Practice in Thrombosis and Haemostasis. 2025-01-01 - 1 citationsLong-Term Efficacy and Safety of Damoctocog Alfa Pegol Prophylaxis in Patients with Haemophilia A Aged 12-<18 Years at Enrolment into PROTECT VIII.Mark T Reding, Mindy Simpson, Jonathan Ducore, Pål Andrè Holme, Monika Maas Enriquez
Acta Haematologica. 2025-01-01
Press Mentions
Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual SummitJune 15th, 2020
FDA Approves JiviAugust 31st, 2018
